Toward radiomics for assessment of response to systemic therapies in lung cancer

Shawn Sun; Florent L. Besson; Binsheng Zhao; Lawrence H. Schwartz; Laurent Dercle

doi:10.18632/oncotarget.27847

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Toward radiomics for assessment of response to systemic therapies in lung cancer

Shawn Sun, Florent L. Besson, Binsheng Zhao, Lawrence H. Schwartz and Laurent Dercle _

PDF | Full Text | How to cite

Oncotarget. 2020; 11:4677-4680. https://doi.org/10.18632/oncotarget.27847

Metrics: PDF 1018 views | Full Text 1843 views | ?

Abstract

Shawn Sun1, Florent L. Besson2, Binsheng Zhao1, Lawrence H. Schwartz1 and Laurent Dercle1

1 Department of Radiology, New York Presbyterian Hospital, Columbia University Medical Center, New York, New York, USA

2 Department of Biophysics, Nuclear Medicine-Molécular Imaging, Hôpitaux Universitaires Paris-Saclay, AP-HP, Université Paris Saclay/CEA/CNRS/Inserm/BioMaps, France

Correspondence to:

Laurent Dercle,

email:

[email protected]

Keywords: positron emission tomography; computed tomography; prognosis; lung cancer; immunotherapy

Received: November 28, 2020 Accepted: November 30, 2020 Published: December 22, 2020

Copyright: © 2020 Sun et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

This editorial comment explains recent developments in radiomics regarding the use of quantitative imaging biomarkers to predict lung cancer sensitivity to a variety of cancer therapies. Tumor response assessment has been a crucial component guiding cancer treatment. Evaluation of treatment response was standardized and classically based on measuring changes in tumor lesion size. Recent breakthroughs in artificial intelligence pave the way for the use of radiomics in tumor response assessment. Such objective techniques would bring a remarkable transformation to conventional methods, which can be inherently subjective. Successful implementation of these technologies would allow for faster and more accurate predictions of treatment efficacy, which will be critical to the advancement of personalized medicine.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27847

Publication Alerts

Research Papers:

Toward radiomics for assessment of response to systemic therapies in lung cancer

Abstract